- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Evolus Inc(EOLS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EOLS
11/13/2026: EOLS (1-star) is currently NOT-A-BUY. Pass it for now.
Evolus Inc is a commercial-stage medical aesthetics company specializing in physician-administered products like its flagship neurotoxin Jeuveau. The company benefits from strong top-line revenue growth, a dedicated aesthetic focus, and an innovative digital loyalty platform driving high clinic retention. Its primary growth opportunity lies in expanding its portfolio internationally and scaling its newly introduced Evolysse dermal filler line. However, the company faces intense competition from larger industry incumbents, execution risks regarding new product acceptance, and ongoing operational investments. It is best suited for growth-oriented investors willing to monitor quarterly revenue expansion, market share metrics, and progress toward sustained net profitability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Evolus exhibits rapid top-line revenue expansion driven by market share gains in the aesthetic neurotoxin sector. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently reacts strongly to quarterly revenue beats and pipeline milestones. |
| Value investor | Weak fit | The company is focused on scaling and growth, rendering traditional near-term value metrics less applicable. |
| Dividend investor | Weak fit | Evolus does not pay a dividend and retains all cash for business reinvestment. |
| Low-risk investor | Weak fit | As a mid-cap growth aesthetic company, it experiences higher volatility and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp price swings based on growth metrics and market sentiment. |
| Valuation risk | Medium / high | Expectations for high future growth leave less room for commercial or financial disappointments. |
| Competition risk (neurotoxin and filler market dominance) | High | Intense rivalry from established industry leaders like AbbVie can pressure market share gains. |
| Business quality | Medium | The company features high gross margins and strong recurring demand, tempered by product concentration. |
| Dividend income | Low / none | Income-focused investors will find no yield support from this growth equity. |
| Execution risk | Medium / high | Successful scaling of international operations and new filler products is critical to meeting long-term targets. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 460.67M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 978.9K shares | Beta 1.34 | 52 Weeks Range 3.86 - 9.31 | Updated Date 11/15/2026 |
52 Weeks Range 3.86 - 9.31 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 16.05% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neurotoxin Sales (Jeuveau) | Direct sales of Jeuveau to physicians, clinics, and medical spas primarily in the United States. | This is the primary engine driving current revenue and gross profits. |
| International & Aesthetic Portfolio | Sales of Jeuveau in international markets (such as Europe under the brand Nuceiva) and emerging sales of dermal fillers. | Represents the secondary growth frontier designed to diversify revenue streams beyond the U.S. neurotoxin market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 13.91 | Enterprise Value 584.23M | Price to Sales(TTM) 1.42 |
Enterprise Value 584.23M | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA -21.5 | Shares Outstanding 66.19M | Shares Floating 48.30M |
Shares Outstanding 66.19M | Shares Floating 48.30M | ||
Percent Insiders 12.03 | Percent Institutions 80.12 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

